Press Releases from Axentis Pharma AG (2 total)
CYSTIC FIBROSIS - LIPOSOMAL TOBRAMYCIN RECEIVES SECOND ORPHAN DRUG DESIGNATION W …
PRE-CLINICAL DATA INDICATE UNIQUE MICROBIOLOGICAL PROFILE FOR ESTABLISHED ANTIBIOTIC
Zurich, 16 July 2009. An innovative treatment for infections of the respiratory tract in cystic fibrosis…
CHRONIC LUNG DISEASE - AXENTIS PHARMA ATTRACTS INVESTMENT INTEREST
Zurich, 2. February 2009. Axentis Pharma AG is to present its recent successes in developing and financing a new therapeutic formulation for treating chronic lung…
Go To Page:
